Sarepta Therapeutics (AB3A) AI Stock Analysis

6 Followers

Sarepta Therapeutics

(Frankfurt:AB3A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Long-term revenue scaleSarepta has materially expanded its commercial revenue base over several years, demonstrating meaningful product adoption and a larger operating platform. This scale can support continued investment in genetic-medicine programs and improve the company’s ability to absorb development costs over the next several quarters.

Negative Factors

ELEVIDYS-driven revenue declineRecent revenue contraction indicates that ELEVIDYS has not yet provided dependable growth after its launch contribution. Continued weakness could reduce operating leverage, constrain investment capacity, and leave overall performance more dependent on the mature PMO franchise during the next two to six months.

Sarepta Therapeutics (AB3A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.79B
Dividend Yield: ―
Average Volume (3M): 198
Price to Earnings (P/E): 185.3
Beta (1Y): 1.16
Revenue Growth: -23.76%
EPS Growth: 62.88%
Country: Germany
Employees: 835
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Sarepta Therapeutics Business Overview & Revenue Model

Company Description

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company...

Sarepta Therapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-8.78%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call conveyed focused optimism, supported by stabilized ELEVIDYS demand, strong PMO performance, raised revenue guidance, positive pipeline data, upcoming DM1 and FSHD readouts, non-GAAP profitability, and nearly $1 billion of cash and investments. These positives were partially offset by year-over-year revenue declines driven by lower ELEVIDYS sales, significant take-or-pay charges and related gross-margin pressure, a third-quarter GAAP operating loss, the termination of ENVISION enrollment, and continued uncertainty around near-term ELEVIDYS growth and the non-ambulatory label.

Positive Updates

Raised 2026 Revenue Guidance

Based on strong PMO performance and stabilization in ELEVIDYS, Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion.

Negative Updates

Decline in Product Revenue

Third-quarter total product revenues were $324 million, a decrease of 13% year-over-year, while first-nine-month product revenues were $983 million, a decrease of 34%. The year-over-year declines were driven by lower ELEVIDYS sales.

Company Guidance

Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion; ELEVIDYS revenue was $83 million in the third quarter and is expected in the fourth quarter to trend in line with Q3, while the PMO franchise is expected to remain strong. Full-year combined non-GAAP R&D and SG&A expense guidance was narrowed to between $800 million and $825 million. The company expects to submit an sBLA for the under-four population mid-next year, complete enrollment of ENDEAVOR Cohort eight by the end of this year and engage with FDA in Q1 2027, share DM1 and FSHD MAD data in the coming weeks, receive higher-dose data early next year, and generate Huntington’s disease proof-of-biology data sometime around mid-year next year.

Sarepta Therapeutics Risk Analysis

Sarepta Therapeutics disclosed 66 risk factors in its most recent earnings report. Sarepta Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Deviations from manufacturing, testing, packaging and distribution processes and procedures could result in manufacturing delays or delays in product release, which may harm our business.Q2, 2026

Sarepta Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AB3A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSHA	49Neutral	$1.39B	-10.13	-56.19%	―	-32.27%	-21.09%
RARE	48Neutral	$1.65B	-3.22	213.22%	―	15.76%	12.63%
QURE	46Neutral	$1.59B	-6.94	-96.34%	―	28.04%	19.12%
WVE	45Neutral	$672.55M	-3.20	-44.48%	―	-35.07%	-45.17%
SLDB	42Neutral	$800.25M	-4.25	-67.78%	―	―	28.59%

* Healthcare Sector Average

Performance Comparison

DE:AB3A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AB3A	Sarepta Therapeutics Inc.	15.16	-0.13	-0.85%
RARE	Ultragenyx Pharmaceutical, Inc.	16.70	-16.20	-49.24%
QURE	uniQure N.V.	24.59	-5.75	-18.97%
WVE	Wave Life Sciences Pte. Ltd	3.42	-3.25	-48.73%
SLDB	Solid Biosciences	7.60	3.30	76.74%
TSHA	Taysha Gene Therapies, Inc.	4.28	0.27	6.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sarepta Therapeutics AI Stock Analysis